Cipla Ltd.

Cipla has leveraged and invested in our manufacturing capital through facilities that are cGMP compliant and approved globally. This has facilitated the company to attain a global leadership position in the pharmaceutical sector.

The confidence of patients and healthcare professionals in our products has strengthened over the years due to consistent and timely delivery of highly dependable products. We continue to strive to retain this confidence by diligently manufacturing high quality medicines and implementing innovative, path breaking technologies to deliver superior quality products.

Taking the principle of 'Caring for Life' forward, we have worked towards enhancing the affordability of medicines worldwide. We were able do this through cost and complexity rationalisation, product portfolio enhancement, process/yield improvements and alternate vendor development.

We have over 1500 products in 65 therapeutic categories available in over 50 dosage forms. These capabilities range from the development of a simple molecule to highly complex multi-chiral centres molecule with a distinction of affordability and highest quality. Our capacities include our own facilities and in licensed facilities which support both generic and the biotech business. Our investments in manufacturing capital include development of new drug delivery systems, facilitation of infrastructure supporting API and formulation developments and strengthening of platform technologies.